Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 826 to 840 of 1058 results for drug therapy

  1. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)

    Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  2. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.

  3. Percutaneous mitral valve leaflet repair for mitral regurgitation (HTG513)

    Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.

  4. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)

    Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.

  5. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

  6. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  7. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.

  8. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

  9. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  10. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

  11. Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

    Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.

  12. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

  13. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  14. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  15. Cor-Knot for tying suture knots in valve surgery (MIB206)

    NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery .